Table 2 Weighted characteristics for the study population between death and survival group, NHANES 2003–2010
Survival | Total death | P | ||
|---|---|---|---|---|
Cardiovascular death | Non-cardiovascular death | |||
Patients, n | 4510 | 553 | 1390 | |
Age, n (%) | < 0.001 | |||
60 | 2472 ( 67.3) | 69 ( 17.8) | 192 ( 20.7) | |
≥ 60 | 2038 ( 32.7) | 484 ( 82.2) | 1198 ( 79.3) | |
Sex, n (%) | 0.680 | |||
Male | 2181 ( 49.7) | 313 ( 50.8) | 728 ( 48.6) | |
Female | 2329 ( 50.3) | 240 ( 49.2) | 662 ( 51.4) | |
Body massing index, n (%) | < 0.001 | |||
Normal weight (< 25.0 kg/m2) | 766 ( 18.1) | 130 ( 25.2) | 366 ( 26.3) | |
Overweight (25.0 – 29.9 kg/m2) | 1466 ( 32.9) | 191 ( 29.9) | 526 ( 36.2) | |
Obesity (≥ 30.0 kg/m2) | 2278 ( 49.0) | 232 ( 44.9) | 498 ( 37.5) | |
Systolic blood pressure, mmHg | 130.0(119.0, 143.0) | 138.0(123.0, 154.0) | 137.0(122.0, 151.0) | < 0.001 |
Diastolic blood pressure, mmHg | 76.0(67.0, 84.0) | 66.0(58.0, 76.0) | 69.0(59.0, 78.0) | < 0.001 |
Lead, μg/dL | 1.5(1.0, 2.1) | 2.0(1.4, 2.8) | 1.9(1.3, 2.7) | < 0.001 |
Race, n (%) | < 0.001 | |||
Mexican American | 766 ( 5.8) | 52 ( 2.9) | 162 ( 3.4) | |
Other Hispanic | 282 ( 3.2) | 22 ( 1.8) | 61 ( 2.1) | |
Non-Hispanic White | 2224 ( 73.5) | 374 ( 82.7) | 898 ( 82.0) | |
Non-Hispanic Black | 1050 ( 12.2) | 93 ( 10.0) | 240 ( 9.8) | |
Other Race | 188 ( 5.3) | 12 ( 2.6) | 29 ( 2.7) | |
Poverty income ratio, n (%) | < 0.001 | |||
< 1.3 | 1217 ( 16.8) | 187 ( 27.3) | 462 ( 25.6) | |
1.3–3.5 | 1705 ( 35.8) | 261 ( 49.4) | 635 ( 47.6) | |
> 3.5 | 1588 ( 47.4) | 105 ( 23.3) | 293 ( 27.8) | |
Education Level, n (%) | < 0.001 | |||
High school or less | 2364 ( 43.1) | 374 ( 64.4) | 888 ( 58.9) | |
College or above | 2146 ( 56.9) | 179 ( 35.6) | 502 ( 41.1) | |
Smoker, n (%) | 0.670 | |||
No | 3683 ( 81.5) | 462 ( 82.9) | 1150 ( 80.8) | |
Yes | 827 ( 18.5) | 91 ( 17.1) | 240 ( 19.2) | |
Drinker, n (%) | < 0.001 | |||
No | 2873 ( 69.8) | 252 ( 47.1) | 617 ( 47.7) | |
Yes | 1637 ( 30.2) | 301 ( 52.9) | 773 ( 52.3) | |
Estimated glomerular filtration rate,ml/min/1.73 m 2 | < 0.001 | |||
< 90 | 2308 ( 49.91) | 476 ( 84.74) | 1140 ( 80.11) | |
≥ 90 | 2202 ( 50.09) | 77 ( 15.26) | 250 ( 19.89) | |
Diabetes, n (%) | < 0.001 | |||
No | 3454 ( 82.2) | 356 ( 65.3) | 897 ( 67.9) | |
Yes | 1056 ( 17.8) | 197 ( 34.7) | 493 ( 32.1) | |
Hyperlipidemia, n (%) | 0.900 | |||
No | 740 ( 16.2) | 85 ( 15.5) | 231 ( 16.4) | |
Yes | 3770 ( 83.8) | 468 ( 84.5) | 1159 ( 83.6) | |
Cardiovascular diseases, n (%) | < 0.001 | |||
No | 3888 ( 88.7) | 304 ( 54.5) | 921 ( 67.4) | |
Yes | 622 ( 11.3) | 249 ( 45.5) | 469 ( 32.6) | |
Cancer, n (%) | < 0.001 | |||
No | 4039 ( 89.3) | 449 ( 80.5) | 1053 ( 74.3) | |
Yes | 471 ( 10.7) | 104 ( 19.5) | 337 ( 25.7) | |
Antihypertensive agents, n (%) | 0.290 | |||
No | 3760 ( 83.9) | 456 ( 80.7) | 1171 ( 82.9) | |
Yes | 750 ( 16.1) | 97 ( 19.3) | 219 ( 17.1) | |
Antidiabetic agents, n (%) | < 0.001 | |||
No | 3811 ( 88.8) | 416 ( 76.1) | 1064 ( 79.4) | |
Yes | 699 ( 11.2) | 137 ( 23.9) | 326 ( 20.6) | |
Antihyperlipidemic agents, n (%) | < 0.001 | |||
No | 3184 ( 72.5) | 308 ( 54.4) | 808 ( 59.1) | |
Yes | 1326 ( 27.5) | 245 ( 45.6) | 582 ( 40.9) | |
Antiplatelet agents, n (%) | < 0.001 | |||
No | 4307 ( 96.5) | 464 ( 85.5) | 1216 ( 88.8) | |
Yes | 203 ( 3.5) | 89 ( 14.5) | 174 ( 11.2) | |